Dr. Wiland, et al, reply
| Autor: | Jean Dudler, Jack F. Bukowski, Piotr Wiland, Stefanie Gaylord, Bonnie Vlahos, Sameer Kotak, Theresa Williams, Ron Pedersen, Douglas J. Veale, Hasan Tahir |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
musculoskeletal diseases
030203 arthritis & rheumatology medicine.medical_specialty business.industry Immunology medicine.disease Rheumatology Etanercept 03 medical and health sciences 0302 clinical medicine Rheumatoid arthritis Internal medicine medicine Physical therapy Immunology and Allergy In patient Methotrexate 030212 general & internal medicine Dosing Sustained remission business medicine.drug |
| Zdroj: | The Journal of rheumatology. 44(2) |
| ISSN: | 0315-162X |
| Popis: | To the Editor: We thank Prof. Bannwarth for his insight into the potential influence of methotrexate (MTX) dosing in the PRIZE clinical trial1. The objective of the PRIZE study was to compare sustained remission rates after 39 weeks of reduced medication in patients with rheumatoid arthritis who had first achieved remission after 52 weeks’ treatment with a combination of etanercept (ETN), 50 mg subcutaneously (SC) once a week, and MTX, orally 10–25 mg once a … Address correspondence to Prof. P. Wiland, Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland. E-mail: pwiland1{at}gmail.com |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|